Aldeyra is conducting Phase 3 clinical trials of reproxalap, our lead investigational RASP inhibitor, in dry eye disease and allergic conjunctivitis. In addition, we have begun enrollment in a Phase 3 clinical trial of ADX-2191 in proliferative vitreoretinopathy.
The links below will take you to information about these studies on clinicaltrials.gov. Medical professionals can also email for more information about clinical trial participation.
CLINICAL TRIAL
Phase 3 TRANQUILITY-2 Trial for Dry Eye Disease
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
CLINICAL TRIAL
Phase 3 INVIGORATE Trial for Allergic Conjunctivitis
A Randomized, Double-Masked, Crossover Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Learn More
CLINICAL TRIAL
Phase 3 GUARD Trial for Proliferative Vitreoretinopathy
A Multi-Center, Randomized, Controlled, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 for the Prevention of Proliferative Vitreoretinopathy